3 Genomic Health Analyst Ratings, Earnings, Dividends and Insider Trades | $GHDX | NASDAQ:GHDX | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Genomic Health Company Profile (NASDAQ:GHDX) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Genomic Health (NASDAQ:GHDX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 5 Sell Rating(s), 4 Hold Rating(s), 4 Buy Rating(s)Consensus Rating:Hold (Score: 1.92)Consensus Price Target: $31.80 (13.61% upside) Analysts' Ratings History for Genomic Health (NASDAQ:GHDX) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/5/2014TheStreetDowngradeHold -> SellView 2/7/2014Credit SuisseDowngradeOutperform -> NeutralView 2/5/2014Bank of AmericaDowngradeUnderperform$30.00 -> $28.00View 2/5/2014JMP SecuritiesLower Price TargetOutperform$38.00 -> $34.00View 2/5/2014Jefferies GroupLower Price Target$33.00 -> $28.00View 12/26/2013ZacksReiterated RatingNeutral -> Neutral$31.00View 11/7/2013BMO Capital MarketsBoost Price TargetUnderperform$18.00 -> $20.00View 11/6/2013Canaccord GenuityLower Price TargetHold$35.00 -> $33.00View 11/6/2013William BlairUpgradeMarket Perform -> OutperformView 10/1/2013Bank of AmericaDowngradeNeutral -> Underperform$36.00 -> $33.00View 9/24/2013ZacksReiterated RatingNeutral -> Neutral$33.00View 9/23/2013Raymond JamesDowngradeMarket Perform -> UnderperformView 8/2/2013MLV & Co.Boost Price TargetHold$30.00 -> $35.00View 6/25/2013Goldman SachsDowngradeNeutral -> Sell$27.00 -> $26.00View 6/18/2013Bank of AmericaDowngradeNeutralView 6/18/2013Leerink SwannReiterated RatingOutperform$41.00View 6/18/2013Bank of AmericaDowngradeBuy -> Neutral$43.00 -> $36.00View 5/31/2013Jefferies GroupInitiated CoverageHold$35.00View 5/10/2013Ladenburg ThalmannBoost Price TargetBuy$36.00 -> $42.00View 5/10/2013Credit SuisseBoost Price TargetOutperform$37.00 -> $40.00View 5/9/2013Canaccord GenuityBoost Price Target$31.00 -> $35.00View 4/22/2013ZacksReiterated RatingNeutral -> Neutral$31.00View 3/27/2013Leerink SwannUpgradeMarket Perform -> OutperformView 2/11/2013ZacksReiterated RatingNeutral -> Neutral$29.00View 1/7/2013ZacksReiterated RatingNeutral -> Neutral$29.00View 11/9/2012ZacksReiterated RatingNeutral -> Neutral$28.00View 10/11/2012Goldman SachsInitiated CoverageNeutral$36.00View 10/2/2012Cowen and CompanyInitiated CoverageOutperformView 9/27/2012JPMorgan Chase & Co.Reiterated RatingNeutralView 9/24/2012Credit SuisseInitiated CoverageOutperform$43.00View 9/24/2012Piper JaffrayReiterated RatingOverweightView 8/17/2012ZacksDowngradeOutperform -> Neutral$38.00View 8/16/2012Bank of AmericaInitiated CoverageBuy$44.00View 8/16/2012Bank of AmericaInitiated CoverageBuyView 7/12/2012Canaccord GenuityReiterated RatingHoldView 7/4/2012ZacksUpgradeNeutral -> Outperform$43.00View 5/18/2012ZacksReiterated RatingNeutral -> Neutral$34.00View 5/3/2012Canaccord GenuityReiterated RatingHoldView (Data available from 3/10/2012 forward) Earnings History for Genomic Health (NASDAQ:GHDX)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView 11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView 7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView 5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView 2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView 11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView 8/8/2012($0.02)$0.06ViewN/AView 5/2/2012($0.02)$0.02ViewN/AView 2/6/2012$0.09$0.08ViewN/AView 11/1/2011$0.03$0.10ViewN/AView 8/3/2011$0.02$0.08ViewN/AView 5/3/2011$0.02($0.01)ViewN/AView 2/8/2011$0.06$0.06ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Genomic Health (NASDAQ:GHDX)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Genomic Health (NASDAQ:GHDX)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.56View 1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00View 1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.00View 12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00View 12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.00View 12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.00View 10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View 10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.00View 10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.00View 9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00View 9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.00View 9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View 9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View 9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.00View 8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00View 8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.00View 8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.00View 8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.00View 7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View 7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View 7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View 7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View 6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View 6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View 6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View 6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View 6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View 6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View 5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View 5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View 5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View 5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View 5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View 5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View 5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View 5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View 5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View 5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View 5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View 2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View 2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View 2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View 11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View 11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View 11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View 11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View 11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View 11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View (Data available from 1/1/2013 forward) About Genomic Health Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation. Headlines: (2/13) What Makes Genomic Health (GHDX) a Strong Sell? (3/6) Diagnostics Marketing Association Names Genomic Health its 2013 Marketer of the Year (2/27) Zacks Rank #5 Additions for Thursday Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: GHDX CUSIP: 37244C10 Key Metrics: Previous Close: $27.9950 Day Moving Average: $28.7338200 Day Moving Average: $30.9914 P/E Ratio: N/AP/E Growth: 1.52Market Cap: $876.8MCurrent Quarter EPS Consensus Estimate: $-0.82 EPS Additional Links: View GHDX on Google FinanceView GHDX on Yahoo FinanceView GHDX's Company Profile on ReutersSearch for Genomic Health Inc. on Google Genomic Health (NASDAQ:GHDX) Chart for Monday, March, 10, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.